Esbriet

Esbriet Drug Interactions

pirfenidone

Manufacturer:

Roche

Marketer:

DKSH
Full Prescribing Info
Drug Interactions
CYP1A2 Inhibitors: Pirfenidone is metabolized primarily (70 to 80%) via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6 and 2E1.
Strong CYP1A Inhibitors: The concomitant administration of ESBRIET and fluvoxamine or other strong CYP1A2 inhibitors (e.g., enoxacin) is not recommended because it significantly increases exposure to ESBRIET (see Pharmacology under Actions). Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. In the event that fluvoxamine or other strong CYP1A2 inhibitors are the only drug of choice, dosage reductions are recommended. Monitor for adverse reactions and consider discontinuation of ESBRIET as needed (see Dosage & Administration).
Moderate CYP1A Inhibitors: Concomitant administration of ESBRIET and ciprofloxacin (a moderate inhibitor of CYP1A2) moderately increases exposure to ESBRIET (see Pharmacology under Actions). If ciprofloxacin at the dosage of 750 mg twice daily cannot be avoided, dosage reductions are recommended (see Dosage & Administration). Monitor patients closely when ciprofloxacin is used at a dosage of 250 mg or 500 mg once daily.
Concomitant CYP1A2 and other CYP Inhibitors: Agents or combinations of agents that are moderate or strong inhibitors of both CYP1A2 and one or more other CYP isoenzymes involved in the metabolism of ESBRIET (i.e., CYP2C9, 2C19, 2D6, and 2E1) should be discontinued prior to and avoided during ESBRIET treatment.
CYP1A2 Inducers: The concomitant use of ESBRIET and a CYP1A2 inducer may decrease the exposure of ESBRIET and this may lead to loss of efficacy. Therefore, discontinue use of strong CYP1A2 inducers prior to ESBRIET treatment and avoid the concomitant use of ESBRIET and a strong CYP1A2 inducer (see Pharmacology under Actions).
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in